Vira Health raised $12M to build a menopause platform — and 8 of its 10 open roles are clinicians who will never see a patient

The $12M Signal: Why a Menopause Startup Is Outpacing Broader Femtech Funding

Vira Health raised $12 million in March 2022, a Series A that closed while femtech funding was still recovering from its 2021 peak. Octopus Ventures led the round, with Optum Ventures participating, and the deal valued the London-based menopause platform at a moment when most digital-health startups watched their multiples compress. The bet rested on a specific thesis: menopause care, long ignored by both the NHS and U.S. employers, had grown into a problem large enough to support a standalone company.

The numbers behind that thesis are stark. Octopus Ventures pointed to a projected one billion women experiencing menopause by 2025, roughly 12% of the global population. In the U.K. alone, menopause accounts for an estimated 14 million lost working days and one million premature career exits annually. Co-founder Andrea Berchowitz, a former McKinsey associate partner who led Middle East operations for the Bill & Melinda Gates Foundation, built Stella around the premise that those women were not getting adequate support from general practitioners, and that employers had a financial incentive to fix that gap.

Vira's £1.5 million seed round, announced in July 2021 from LocalGlobe and MMC Ventures, had already validated the concept. The Series A sent a different signal. Optum Ventures, the U.S. health-plan venture arm, joined the cap table explicitly to help Vira cross the Atlantic. That U.S. expansion plan, targeting the second half of 2022 for launch, is what the majority of the new capital funds: building out a telehealth layer that lets Stella users book virtual physician consultations and obtain prescriptions for hormone therapy, moving the app from an information service toward a regulated medical product.

That trajectory mirrors what Clue did with its FDA-cleared digital contraceptive, and Berchowitz has said the company is open to pursuing regulatory clearance as the product scope expands. Early feasibility data, collected between December and February, showed 75% of women who completed their Stella treatment plans reported improved symptoms. Vira polls users weekly for a less formal wellbeing score alongside those outcomes.

The broader femtech context makes the raise stand out. Startups like Elektra Health, Gennev, Peppy, and Lisa Health have all entered the menopause space, but none had closed a round of this size by early 2022. Berchowitz described the fundraising process as grueling, noting that one U.S. investor had reviewed 30 menopause startups without writing a check. The skepticism was not about digital delivery (Sleepio, Kaia Health, and Quit Genius had already proven that model) but about whether American women would seek menopause care through an app. Vira's answer was to target investors who already understood digital therapeutics, then use Optum's U.S. health-plan network to shortcut the employer-sales learning curve.

That employer channel is where the workforce story begins.

What 10+ Open Roles Reveal About Vira's Operating Model

Vira Health's careers page lists 10 open positions as of this writing, and the breakdown reveals more about the company's operating model than any pitch deck could. Eight of those roles are clinical. One sits in care operations. One is in sales. The engineering and product teams aren't hiring externally at all.

The clinical roles split into two tracks. The larger is the Clinical Educator series, seven part-time, remote positions each tagged to a specific language: Mandarin, French Canadian, German, Hindi, Italian, Portuguese, and Dutch. The second is a single full-time remote role: Nurse Practitioner – Women's Midlife Health. Together, they describe a company building a distributed, multilingual clinical workforce that operates almost entirely through virtual sessions and asynchronous content.

The Clinical Educator job description is unusually specific about what the role is not. These are 15-to-30-minute virtual education sessions. No clinical evaluation. No prescribing. No ongoing management. No provider-patient relationship is formed, which the posting notes eliminates licensing and accreditation limitations across jurisdictions. That's the legal architecture that makes a part-time, worldwide, multi-language clinical workforce possible. Educators need an active license in their country of practice and a minimum of three years in women's health (OB/GYN, reproductive health, menopause care, or a related specialty), but they are not delivering care in the traditional sense.

What they are doing, beyond the live sessions, is producing content. The job descriptions include creating articles, care plans, videos, and webinar materials for Vira's Member Zone, reviewing existing content for clinical accuracy, and developing materials that are culturally sensitive for diverse geographies. The role is closer to a clinical content producer who also takes calls than a traditional telehealth nurse. Multi-lingual capability is explicitly preferred, with French, Arabic, German, Chinese, Japanese, Hindi, Dutch, and Spanish called out.

The one full-time clinical role, Nurse Practitioner, Women's Midlife Health, suggests Vira is also building capacity for a higher-acuity layer of the platform, likely the Stella app's personalized treatment plans for menopause and perimenopause. That role sits alongside the educators but implies a different scope of practice.

The non-clinical hires fill in the gaps. The Member Operations Specialist handles telehealth patient safety and language localization. The Sales Lead for Employer Sales, Americas carries a posted range of $80,000 to $100,000 base with $150,000 in potential commission and another $150,000 in bonus, a structure that signals aggressive employer-market expansion across North and South America.

The hiring mix tells a clear story: Vira is staffing up to deliver menopause and midlife care as a global, language-localized, education-first service sold to employers. The part-time, remote, multi-language educator model keeps clinical costs flexible while the content output scales across markets. The single NP hire and the sales lead are the only full-time positions; everything else is built to flex with member demand.

Why Vira Sells to Employers, Not Individuals

Vira Health's Stella app didn't start as a benefits play. It launched as a direct-to-consumer menopause telehealth service operating in the UK, US, and South Africa. But the company's newer product, the Vira Health Member Zone, a global employee health benefits platform, represents a deliberate shift: selling to employers and insurers rather than individuals, and packaging women's health as workforce infrastructure rather than consumer wellness.

The numbers behind that pivot are stark. Thirty percent of women consider leaving or have left their jobs due to menopause symptoms. Forty-seven percent say health symptoms affect their work performance. And $1.8 billion in US workdays are lost annually to menopause symptoms, according to figures Vira's co-founders cite regularly. Those are the data points Berchowitz and Dr. Rebecca Love now pitch to HR leaders and benefits procurement teams.

"We started Vira Health because the healthcare system failed women at some of the most significant moments of their lives," Berchowitz said in a statement reported by Femtech Insider. "Employers have a real opportunity to change that and a real business reason to act."

The business model is B2B2C: Vira sells the Member Zone platform to employers and health plans, who offer it as an employee benefit. Workers get access to Stella for menopause care, the Lowdown for contraception and hormonal health, and a broader care-navigation layer covering fertility, pregnancy, parenting, and men's health. The platform is available in more than 100 countries and over 20 languages, with content localized rather than just translated. TELUS Health was the first distribution partner, offering the platform through its Employee Assistance Programme. Other partners listed on Vira's site include Aon, Optum, UnitedHealthcare, Vitality, and Discovery.

That partner roster tells you who's buying. These are not startups experimenting with a pilot. They are large-scale health plans and benefits platforms that manage millions of members and need vendor solutions that work across jurisdictions. Vira's pitch to them is simple: one platform covering every life stage, replacing a patchwork of fertility vendors, EAP referrals, and menopause programs that most employees never use.

The employer value proposition Vira markets is retention and productivity, not just health outcomes. The company's site lists reduced absenteeism, lower healthcare costs, improved retention, and demonstrated inclusion as the four business outcomes the platform targets. One in six people need fertility support, 24% of women have health issues that affect their daily life, and 57% of employees have taken or would consider taking a new job for better reproductive health benefits, figures repeated across Vira's marketing.

What makes this a structural shift rather than a feature add-on is the framing. Vira is not selling menopause support as a DEI initiative or a wellness perk. It is selling it as workforce infrastructure, the same category as mental health benefits or retirement plans. Dr. Frances Yarlett, a women's health specialist who has worked with the company, made this explicit in a LinkedIn post about England's Women's Health Strategy: "At Vira Health, this is what we already do. We support women through every stage of their health journey, through their employers, with clinically-backed care that women want and need."

That language, "through their employers," is the key. It positions the employer as the distribution channel and the economic buyer, which changes the unit economics entirely. A consumer menopause app fights for individual subscriptions. A benefits platform gets embedded in annual contracts with enterprise clients covering hundreds of thousands of employees.

The timing matters. Healthy life expectancy in the UK has fallen by two years over the past decade, now sitting at just under 61, according to The Health Foundation. That means most workers are already managing chronic health conditions before they stop working. Vira's argument to employers is that midlife (perimenopause, menopause, fertility, hormonal health) is the inflection point where intervention has the most effect on long-term workforce participation.

Whether employers will actually pay for this at scale remains the open question. The platform's clinical outcomes data, 80% of members feel better, 88% would recommend to a colleague, 75% report improved menopause symptoms, is promising but self-reported. The real test is whether procurement teams at mid-market companies, not just multinationals with global workforces, see menopause benefits as worth the line item. Vira's Series A suggests investors are betting they will.

Does Menopause Care Need a Clinic? What Vira's Job Posts Say

Vira Health's hiring spree isn't just about headcount; it's a structural bet that menopause care doesn't need a clinic to work. The company's open roles lean heavily toward remote clinical educators, virtual care coordinators, and distributed content teams, a pattern that signals how the broader women's-health sector is rethinking where and how care gets delivered.

The remote-first model isn't a pandemic hangover. It's a deliberate design choice that solves a specific problem: the U.S. has a thin supply of clinicians trained in menopause-specific care, and they cluster in major metros. By building a distributed workforce, Vira can recruit nationally, pulling from nursing, health coaching, and patient-education talent pools that traditional brick-and-mortar practices can't access. A clinician in rural Ohio with a background in women's health becomes viable for a platform that never asks a patient to drive 45 minutes to an appointment.

This matters for workforce planning across the femtech sector. The companies that scale menopause benefits to employer populations of 50,000 or more can't staff that volume with in-person clinics. They need virtual care infrastructure, and that infrastructure needs people: care navigators who can work asynchronously, health educators comfortable with video and chat-based coaching, and clinical content producers who can translate evidence-based protocols into digital-first patient experiences.

The hiring pattern also reveals a cost logic. Remote clinical roles let Vira match compensation to regional labor rates rather than anchoring everything to San Francisco or New York salary bands. That's not a minor detail when you're selling to employers who benchmark benefits spend against tight per-employee-per-month targets. A distributed workforce keeps unit economics in check while expanding the addressable talent pool.

For operators watching this space, the takeaway is clear: the next wave of women's-health delivery won't be built on real estate. It will be built on clinical workforces designed from the ground up for virtual care, with all the workforce-design challenges that implies, from asynchronous care protocols to licensure compliance across state lines. Vira's job board is a blueprint for what that looks like in practice.

The Data Moat Nobody Talks About

Vira Health's Stella app started as a menopause-tracking tool: symptom logs, lifestyle guidance, evidence-based content about hormonal transitions. That consumer-facing product is the surface. Underneath it sits something harder to replicate: a growing dataset of longitudinal female health records spanning fertility, pregnancy, postpartum, and midlife, built across more than 100 countries and 20 languages.

Longitudinal data, the same person's health information tracked over years, not a single snapshot, is the asset that makes the platform defensible. Most health datasets are cross-sectional: one visit, one survey, one moment. Stella collects ongoing self-reported symptoms, behavioral patterns, and engagement with clinical content across hormonal life stages. That structure lets Vira map how, say, someone's perimenopausal symptom profile connects to earlier pregnancy complications or postpartum mental health patterns. No single data point is the moat. The moat is the connections across time.

Female-specific longitudinal data has a structural scarcity problem working in Vira's favor. Medical research historically underrepresented women in clinical trials, and the data that does exist skews toward narrow reproductive windows (pregnancy, contraception) rather than the full hormonal arc. Employers and insurers looking to build midlife women's benefits have almost no evidence base to work from. Vira is assembling one, user by user, through Stella's self-care and coaching framework.

The company's own pitch frames it plainly: combine data, clinical best practice, and behavior change to solve health problems that affect billions. The data layer feeds the clinical content, the content drives engagement, and the engagement generates more data. That loop is what makes the platform sticky for employer and insurer buyers: they're not just purchasing a menopause benefit, they're plugging into a system that gets more informed about their workforce's health over time.

The competitive implication is straightforward. Incumbent health plans entering women's health can license clinical guidelines. They can build content libraries. What they can't easily build is years of patient-generated longitudinal data tied to real-world engagement across multiple hormonal life stages. That's the gap Vira is racing to widen before the market matures.

Crowded and Underserved at the Same Time

Vira Health is building its menopause platform inside a market that is both crowded and oddly underserved. The global femtech sector is projected to reach $60.01 billion by 2027, according to Emergen Research, growing at a compound annual rate of 15.6%. That growth has attracted a long list of startups and, increasingly, the attention of large health plans that see women's health as the next benefits battleground.

The menopause-specific corner where Vira operates is narrower but heating up. VentureRadar lists Elektra Health (founded 2019), Gennev (2015), Midi Health (2021), Visana Health (2019), and Science and Humans (2018) as direct or near-direct competitors. Gennev reports having served over 220,000 women with its telehealth menopause clinic. Midi Health, which raised funding in 2022, sells virtual perimenopause and menopause care covered by insurance. Elektra Health combines telemedicine with evidence-based education and community support. These companies share Vira's basic thesis: that midlife women's care is fragmented, stigmatized, and ripe for a digital-first platform.

Where Vira diverges is in its B2B2C distribution. Rather than selling directly to consumers or building a brand that competes with Flo Health's 300 million downloads or Clue's 10 million users, Vira sells through employers and insurers. Its platform, anchored by the Stella menopause app, is designed to plug into existing benefits infrastructure. That puts it in a different competitive set than the consumer-facing apps and closer to companies like Maven Clinic, which reported $146.8 million in 2023 revenue by selling virtual women's and family health to employers, or Peppy, the UK-based menopause benefits platform that grew an estimated 282% per year and raised $45 million in a 2023 Series B.

The employer-channel strategy also means Vira increasingly rubs up against large health insurers expanding their own women's health offerings. UnitedHealthcare, Aon, Optum, and TELUS Health all appear on Vira's partner logo page, suggesting the company is positioning itself as a layer that incumbents white-label rather than a consumer brand that displaces them.

The funding environment makes this positioning pragmatic. Femtech venture capital has tightened since the 2021 peak of $2.4 billion in sector funding, according to FemTech Analytics. Forbes reports that femtech still captures only about 1.4% of total healthcare capital. In that climate, a $12 million raise with a clear employer-sales motion looks more durable than a consumer app burning through marketing spend to acquire users who churn after one cycle.

Five Lessons for Building a Clinical-AI Hybrid Workforce

Vira Health's hiring blitz is a concrete case study in a broader shift: the merging of clinical operations and AI-enabled infrastructure into a single workforce. For operators building similar teams, whether at a femtech startup, a health plan expanding into women's health, or a hospital system launching a virtual menopause program, five lessons emerge from what Vira is doing and from the wider talent market.

1. Hire the clinical educator before the algorithm. Vira's job posts for nurse educators, care navigators, and clinical content producers sit alongside data and engineering roles. That's not accidental. The bottleneck in AI-enabled women's health isn't model accuracy; it's patient trust and clinical adoption. The operators who will scale fastest are those who staff the education layer at parity with the tech layer. LevelUP Human Capital Solutions' 2025 Healthcare Talent Playbook found that 87% of healthcare leaders list staffing shortages as their biggest challenge. The shortage isn't just physicians. It's the mid-level clinical workforce that translates a platform into a care plan a patient will follow.

2. Design for autonomy, not just remote. Telehealth hiring guidance from CX Embassy draws a line that more operators need to internalize: flexibility without autonomy is a half-sell. Vira's remote-first model works because it pairs distributed clinicians with decision-making authority over caseloads and patient interactions. The alternative, remote work with the same rigid scheduling as in-person clinics, drives attrition. LevelUP's research shows that 70% of healthcare job seekers cite salary as the most important factor in job selection, but autonomy and scheduling flexibility are the close second that determines whether they stay.

3. Treat longitudinal data as a workforce tool, not just a product feature. Vira's Stella app generates patient-reported outcome data across the menopause transition. Operators building clinical-AI hybrid teams should design roles where that data flows back to clinicians in usable form, not buried in a dashboard no one opens. This means hiring or training clinicians who can interpret population-level trends, not just respond to individual symptom reports. The Digital Medicine Society's Playbook for Digital Clinical Measures makes this point explicitly: measures must matter to patients, and that requires a workforce trained to act on what the measures reveal.

4. Compress hiring timelines or lose candidates. LevelUP's fast-track recruitment process targets a 24-to-48-hour turnaround at every stage from resume review to verbal offer. Their case study shows a healthcare client that cut decision-making from 22 days to 5-8 days saw offer acceptance rates jump from 40% to 95%. For a clinical-AI hybrid role, where the candidate pool is small and the competition from Big Tech salaries is real, slow hiring is a structural disadvantage. Operators should audit their current clinical hiring timeline against this benchmark.

5. Build the retention infrastructure before you scale the headcount. The healthcare talent data is unambiguous on why people leave. One in three healthcare workers reports at least one symptom of burnout. Only 23% of U.S. healthcare workers trust their leadership to act in their best interest. Vira's early-stage advantage is that it can embed well-being structures (peer support, manageable caseloads, clinician input into platform design) before they become retrofit problems at 50 or 100 employees. Operators who wait until turnover is already high to invest in retention are solving the wrong problem.

The clinical-AI hybrid workforce isn't a future-state aspiration. It's what Vira Health is hiring for this quarter. The operators who move fastest on these five lessons will be the ones staffing the next generation of women's-health platforms, and the ones whose patients actually see the outcomes the technology promises.

Working in frontier tech? Zero G Talent tracks the openings: browse frontier tech jobs, openings at ASML, Stripe and Waymo, and the people building the field.